Alogliptin benzoate. Dipeptidyl-peptidase IV (DPP IV) inhibitor treatment of type 2 diabetes

Drugs of the Future

Volumn 33, Issue 1, 2008, Pages 7-12

  Wang, Y ^a   Serradell, N ^b   Rosa, E ^b   Bolos J ^b  

^a IBC   (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 (3 AMINO 1 PIPERIDINYL) 1 (2 CYANOBENZYL) 3 METHYLURACIL; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREVALENCE; SINGLE DRUG DOSE; TREATMENT FAILURE;

EID: 40949105273     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.01.1171514     Document Type: Article

References (37)

1. Feng, J., Gwaltney, S.L., Stafford, J.A. et al. (Takeda San Diego, Inc.). Dipeptidyl peptidase inhibitors. EP 1586571, JP 2005263780, US2005261271, WO 2005095381.
2. Feng, J., Zhang, Z., Wallace, M.B. et al. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007, 50(10): 2297-300.
3. Feng, J., Gwaltney, S.L., Stafford, J.A. et al. (Takeda Pharmaceutical Co., Ltd.). WO 2007035629.
4. Zimmet, P., Alberti, K.G., Shaw, J. Global and societal implications of the diabetes epidemic. Nature 2001, 414(6865): 782-7.
5. Diabetes. http://wwwwhoint/mediacentre/factsheets/fs312/en/ indexhtml, Accessed November 28, 2007.
6. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998, 21(2): 296-309.
7. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organisation, Department of Noncommunicable Disease Surveillance, Geneva, 1999.
8. Zimmet, P. Diabetes epidemiology as a tool to trigger to diabetes research and care. Diabetologia 1999, 42(5): 499-518.
9. Lebovitz, H. Insulin secretagogues: Old and new. Diabetes Rev 1999, 7: 139-53.
10. Bloomgarden, Z.T. Exploring treatment strategies for type 2 diabetes. Diabetes Care 2007, 30(10): 2737-45.
11. Chyan, Y.-J, Chuang, L.-M. Dipeptidyl peptidase-IV inhibitors: An evolving treatment for type 2 diabetes from the incretin concept. Rec Patents Endocr Metab Immune Drug Discov 2007, 1(1): 15-24.
12. Gwaltney, S. II, Aertgeerts, K., Feng, J. et al. Design and synthesis of potent, selective, and orally efficacious DPP4 inhibitors accelerated by high-throughput structural biology. 231st ACS Natl Meet (March 26-30, Atlanta) 2006, Abst MEDI 18.
13. Takeda's investigational compound SYR-322 for treatment of diabetes enters into phase 3 clinical stage. Takeda Pharmaceutical Co., Ltd. Press Release, January 20, 2006.
14. Christopher, R.J., Davenport, M., Gwaltney, S. et al. Pharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, in rats, dogs, and monkeys. 66th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, Washington, D.C.) 2006, Abst 452-P.
15. Moritoh, Y., Takeuchi, K., Kataoka, O., Asakawa, T., Odaka, H. Chronic administration of alogliptin (SYR-322), a novel dipeptidyl peptidase-IV inhibitor, improved beta-cell function in ob/ob mice. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 511-P.
16. Takeuchi, K., Moritoh, Y., Asakawa, T., Kataoka, O., Shi, L., Odaka, H. Alogliptin (SYR-322) is a novel, potent, highly selective dipeptidyl peptidase-IV inhibitor that improves glucose tolerance and beta cell function in ob/ob mice. 43rd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 17-21, Amsterdam) 2007, Abst 0878.
17. Moritoh, Y., Takeuchi, K., Kataoka, O., Asakawa, T., Odaka, H. Effects of combination treatment with alogliptin (SYR-322), a novel dipeptidyl peptidase-IV inhibitor, and pioglitazone on glycemic control in ob/ob mice. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 2151-PO.
18. Asakawa, T., Suzuki, N., Moritoh, Y., Kataoka, O., Takeuchi, K., Odaka, H. A novel dipeptidyl peptidase-IV inhibitor, alogliptin (SYR-322), is effective in a new rat model of sulfonylurea-induced secondary failure. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 2149-PO.
19. Takeuchi, K., Moritoh, Y., Asakawa, T., Kataoka, O., Zhang, Z., Odaka, H. Effects of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, alone or in combination with pioglitazone in obese and non-obese type 2 diabetes model rats and rice. 66th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, Washington, D.C.) 2006, Abst 2010-PO.
20. Christopher, R., Covington, P., Davenport, M. et al. Pharmacokinetics, pharmacodynamics, and tolerability of single rising doses of the dipeptidyl peptidase-IV inhibitor alogliptin benzoate (SYR-322) in healthy male subjects. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 495-P.
21. Christopher, R., Covington, P., Davenport, M., Fleck, P., Mekki, Q., Wann, E., Karim, A. Single-rising-dose pharmacokinetic, pharmacodynamics, and tolerability of alogliptin benzoate (SYR-322), a novel, dipeptidyl peptidase-IV inhibitor, in healthy male subjects. 43rd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 17-21, Amsterdam) 2007, Abst 0891.
22. Christopher, R., Covington, P., Davenport, M., Fleck, P., Mekki, Q., Wann, E., Karim, A. Pharmacokinetics, pharmacodynamics, and tolerability of multiple doses of alogliptin benzoate (SYR-322), a dipeptidyl peptidase-IV inhibitor, in patients with type 2 diabetes. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 499-P.
23. Karim, A., Fleck, P., Dorsey, D., Zhang, W., Mekki, Q., Preston, RA. Single dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment. 36th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 9-11, San Francisco) 2007, Abst 107.
24. Long-term, open-label extension study to investigate the long-term safety in subjects with type 2 diabetes (NCT00306384). ClinicalTrials.gov Web site, January 9, 2008.
25. A study to evaluate SYR-322 25 plus pioglitazone HCl (ACTOS®) for the treatment of subjects with inadequately controlled type 2 diabetes (NCT00432276). ClinicalTrials.gov Web site, January 9, 2008.
26. Placebo-controlled study of the combination of SYR-322 and pioglitazone HCl in the treatment of type 2 diabetes (NCT00328627). ClinicalTrials.gov Web site, January 9, 2008.
27. Study of SYR-322 combined with pioglitazone in the treatment of type 2 diabetes (NCT00286494). ClinicalTrials.gov Web site, January 9, 2008.
28. Study of SYR-322 combined with metformin in the treatment of type 2 diabetes (NCT00286442). ClinicalTrials.gov Web site, January 9, 2008.
29. Study of SYR-322 combined with a sulfonylurea in the treatment of type 2 diabetes (NCT00286468). ClinicalTrials.gov Web site, January 9, 2008.
30. Study of SYR-322 combined with insulin in the treatment of type 2 diabetes (NCT00286429). ClinicalTrials.gov Web site, January 9, 2008.
31. Study of SYR-322 in the treatment of type 2 diabetes (NCT00286455). ClinicalTrials.gov Web site, January 9, 2008.
32. A study to evaluate SYR-322 plus pioglitazone HCl (Actos®), SYR-322 alone, or pioglitazone alone for the treatment of type 2 diabetes (NCT00395512). ClinicalTrials.gov Web site, January 9, 2008.
33. Takeda submits new drug application for alogliptin (SYR-322) in the U.S. Takeda Pharmaceutical Co., Ltd. Press Release, January 4, 2008.
34. Karim, A., Fleck, P., Joseph, M., Laurent, A., Munsaka, M., Wann, E., Mekki, Q. No pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 2117-PO.
35. Fleck, P., Karim, A., Harris, S., Moore, R., Munsaka, M., Wann, E., Mekki, Q. Lack of effect of multiple doses of alogliptin benzoate (SYR-322) on the pharmacokinetics of glyburide in healthy subjects. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 2135-PO.
36. Covington, P., Christopher, R., Davenport, M., Fleck, P., Mekki, Q., Wann, E., Karim, A. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 2136-PO.
37. Karim, A., Harris, S., Fleck, P., Moore, R., Zhang, W., Mekki, Q. Assessment of drug interaction between alogliptin benzoate (SYR-322): A highly selective dipeptidyl peptidase-1 inhibitor, and warfarin at steady state. 36th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 9-11, San Francisco) 2007, Abst 106.